FI
BLRX

Fosun International’s BioLineRX BLRX Stock Holding History

Fosun International’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,217
Closed -$263K – 246
2019
Q2 		$263K Hold
1,217
– – 0.02% 266
2019
Q1 		$313K Sell
1,217
-1,045
-46% -$304K 0.02% 252
2018
Q4 		$611K Hold
2,262
– – 0.04% 194
2018
Q3 		$1.41M Buy
+2,262
New +$1.24M 0.07% 117

Other funds holding BLRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
NFG
Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fosun International's BLRX Position: Q3 2019 in Review

Fosun International sold out of BioLineRX (BLRX) in Q3 2019, closing a stake of 1,217 shares — an estimated $263K sold.

Fosun International first reported a position in BLRX in Q3 2018 and held it in 4 quarters. The position peaked at $1.41M in Q3 2018. 15 funds tracked by Wall St. Rank hold BLRX as of Q3 2019.

  • Fosun International reported no remaining BioLineRX position as of Q3 2019 after selling out during the quarter.
  • Fosun International sold 1,217 BioLineRX shares in Q3 2019, an estimated $263K.
  • Fosun International first reported a position in BioLineRX in Q3 2018 and held it in 4 quarters.
  • Fosun International's BioLineRX position peaked at $1.41M in Q3 2018.
  • 15 funds tracked by Wall St. Rank held BioLineRX as of Q3 2019.

Based on Fosun International's 13F filing for Q3 2019, filed 12 Nov 2019.